Addition of Astatine-211-Labeled Anti-CD45 Antibody to TBI as Conditioning for DLA-Identical Marrow Transplantation: A Novel Strategy to Overcome Graft Rejection in a Canine Presensitization Model: "Radioimmunotherapy to Overcome Transfusion-Induced Sensitization".

[1]  E. Warren.  Biology of the Human Graft‐versus‐Tumor Response and How to Exploit It , 2016 .

[2]  Lloyd H. Michael,et al.  The Guide for the Care and Use of Laboratory Animals. , 2016, ILAR journal.

[3]  B. Miller,et al.  α-Imaging Confirmed Efficient Targeting of CD45-Positive Cells After 211At-Radioimmunotherapy for Hematopoietic Cell Transplantation , 2015, The Journal of Nuclear Medicine.

[4]  B. Sandmaier,et al.  Reagents for astatination of biomolecules. 6. An intact antibody conjugated with a maleimido-closo-decaborate(2-) reagent via sulfhydryl groups had considerably higher kidney concentrations than the same antibody conjugated with an isothiocyanato-closo-decaborate(2-) reagent via lysine amines. , 2012, Bioconjugate chemistry.

[5]  R. Storb,et al.  Durable donor engraftment after radioimmunotherapy using α-emitter astatine-211-labeled anti-CD45 antibody for conditioning in allogeneic hematopoietic cell transplantation. , 2012, Blood.

[6]  R. Storb,et al.  Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211. , 2009, Cancer research.

[7]  G. Sgouros.  Alpha-particles for targeted therapy. , 2008, Advanced drug delivery reviews.

[8]  D. Scheinberg,et al.  The promise of targeted {alpha}-particle therapy. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[9]  M. Brechbiel,et al.  Radioimmunotherapy with Bismuth-213 as Conditioning for Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Dogs: A Dose Deescalation Study , 2004, Transplantation.

[10]  Allen R. Chen,et al.  Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[11]  M. Brechbiel,et al.  Bismuth 213-labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow grafts. , 2002, Blood.

[12]  R. Storb,et al.  DLA-DRB1 and DLA-DQB1 histocompatibility typing by PCR-SSCP and sequencing. , 1998, Tissue antigens.

[13]  J. Humm,et al.  Radioimmunotherapy with alpha-emitting nuclides , 1998, European Journal of Nuclear Medicine.

[14]  R. Storb,et al.  Characterization of monoclonal antibodies that recognize canine CD34. , 1998, Blood.

[15]  H. Deeg,et al.  Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. , 1997, Blood.

[16]  E. Ostrander,et al.  Histocompatibility testing of dog families with highly polymorphic microsatellite markers. , 1996, Transplantation.

[17]  K. Magnusson,et al.  Liver cell uptake and degradation of soluble immunoglobulin G immune complexes in vivo and in vitro in rats , 1996, Hepatology.

[18]  E. Bryant,et al.  USE OF (CA)n POLYMORPHISMS TO DETERMINE THE ORIGIN OF BLOOD CELLS AFTER ALLOGENEIC CANINE MARROW GRAFTING , 1994, Transplantation.

[19]  H. Deeg,et al.  Gamma-irradiation of pretransplant blood transfusions from unrelated donors prevents sensitization to minor histocompatibility antigens on dog leukocyte antigen-identical canine marrow grafts. , 1994, Transplantation.

[20]  R. Vessella,et al.  Preparation and evaluation of para-[211At]astatobenzoyl labeled anti-renal cell carcinoma antibody A6H F(ab')2. In vivo distribution comparison with para-[125I]iodobenzoyl labeled A6H F(ab')2. , 1993, Nuclear medicine and biology.

[21]  G. Sale,et al.  PREVENTION OF TRANSFUSION‐INDUCED SENSITIZATION TO MINOR HISTOCOMPATIBILITY ANTIGENS ON DLA‐IDENTICAL CANINE MARROW GRAFTS BY GAMMA IRRADIATION OF MARROW DONOR BLOOD , 1991, Transplantation.

[22]  R. Storb,et al.  Canine models of bone marrow transplantation. , 1990, Laboratory animal science.

[23]  C. Caldwell,et al.  Alterations of HLe-1 (T200) fluorescence intensity on acute lymphoblastic leukemia cells may relate to therapeutic outcome. , 1987, Leukemia research.

[24]  H. Deeg,et al.  The canine major histocompatibility complex. Population study of DLA-D alleles using a panel of homozygous typing cells. , 2008, Tissue antigens.

[25]  M. Kadin,et al.  Immunologic markers in the differential diagnosis of small round cell tumors from lymphocytic lymphoma and leukemia. , 1983, American journal of clinical pathology.

[26]  R. Storb,et al.  Analysis of cytotoxic effector cell function in patients with leukemia or aplastic anemia before and after marrow transplantation. , 1980, Journal of immunology.

[27]  R. Storb,et al.  Histocompatibility and marrow transplantation. , 1979, Transplantation Proceedings.

[28]  H. Deeg,et al.  Rejection of marrow from DLA-identical canine littermates given transfusions before grafting: antigens involved are expressed on leukocytes and skin epithelial cells but not on platelets and red blood cells. , 1979, Blood.

[29]  R. Storb,et al.  Effect of six weekly transfusions on canine marrow grafts: tests for sensitization and abrogation of sensitization by procarbazine and antithymocyte serum. , 1976, Journal of immunology.

[30]  R. Storb,et al.  Effect of prior blood transfusions on marrow grafts: abrogation of sensitization by procarbazine and antithymocyte serum. , 1974, Journal of immunology.

[31]  R. Storb,et al.  The influence of transfusions from unrelated donors upon marrow grafts between histocompatible canine siblings. , 1971, Journal of immunology.

[32]  R. Storb,et al.  The effect of prior transfusion on marrow grafts between histocompatible canine siblings. , 1970, Journal of immunology.